{"id":685803,"date":"2024-01-25T15:52:02","date_gmt":"2024-01-25T15:52:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=685803"},"modified":"2024-01-25T15:52:02","modified_gmt":"2024-01-25T15:52:02","slug":"crohns-disease-pipeline-emerging-drugs-clinical-trials-fda-approvals-2024-updated","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/crohns-disease-pipeline-emerging-drugs-clinical-trials-fda-approvals-2024-updated_685803.html","title":{"rendered":"Crohn&#8217;s Disease Pipeline, Emerging Drugs, Clinical Trials, FDA Approvals 2024 (Updated)"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1706180579.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Crohn&#039;s Disease Pipeline, Emerging Drugs, Clinical Trials, FDA Approvals 2024 (Updated)\" src=\"https:\/\/www.abnewswire.com\/uploads\/1706180579.jpeg\" alt=\"Crohn&#039;s Disease Pipeline, Emerging Drugs, Clinical Trials, FDA Approvals 2024 (Updated)\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s, &ldquo;<strong>Crohn&rsquo;s Disease Pipeline Insight 2024<\/strong>&rdquo; report provides comprehensive insights about 90+ companies and 90+ pipeline drugs in Crohn&rsquo;s Disease pipeline landscape. It covers the Crohn&#8217;s Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Crohn&#8217;s Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Crohn&#8217;s Disease Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>DelveInsight&rsquo;s Crohn&#8217;s Disease pipeline report depicts a robust space with 90+ active players working to develop 90+ pipeline therapies for Crohn&#8217;s Disease treatment.<\/li>\n<li>The leading companies working in the Crohn&rsquo;s Disease Market include <em>Janssen, RedHill Biopharma, Amgen, Pfizer, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Abbvie, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, Priothera<\/em>, and others.<\/li>\n<li>Promising Crohn&rsquo;s Disease Pipeline Therapies in the various stages of development include <em>Etrasimod, Infliximab, MEDI2070, Filgotinib, Risankizumab 600 mg IV, CT-P13<\/em>, and others.<\/li>\n<li><strong><em>January 2024: Pfizer<\/em><\/strong> announced a study of Phase 3 clinical trials for Etrasimod. This is a Phase 2\/3 study that comprises 5 substudies designed to evaluate the efficacy, safety, and tolerability of oral etrasimod as therapy in adult participants with moderately to severely active Crohn&#8217;s disease (CD) who are refractory or intolerant to at least 1 of the current therapies for CD (ie, corticosteroids, immunosuppressants, or biologics).<\/li>\n<li><strong><em>January 2024: AstraZeneca<\/em><\/strong> announced a study of Phase 1 clinical trials for AZD7798. This study will assess the safety, tolerability, immunogenicity, and pharmacokinetics (PK), and explore the pharmacodynamics (PD) following single ascending dose administration and repeat dose administration in healthy subjects and patients with Crohn&#8217;s disease.<\/li>\n<li><strong><em>January 2024: AbbVie<\/em><\/strong> announced a study of Phase 3 clinical trials for Risankizumab SC. A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of Risankizumab Subcutaneous Induction Treatment in Subjects With Moderately to Severely Active Crohn&#8217;s Disease.<\/li>\n<li><strong><em>January 2024: Prometheus Biosciences Inc.,<\/em><\/strong> announced a study of Phase 2 clinical trials for PRA023 IV. The purpose of this study is to assess the safety and efficacy of PRA023 in participants with moderately to severely active Crohn&#8217;s Disease.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request a sample and discover the recent advances in Crohn&#8217;s Disease Treatment Drugs @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/crohns-disease-cd-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Crohn&#8217;s Disease Pipeline Report<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">In the Crohn&#8217;s Disease pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Crohn&#8217;s Disease clinical trials studies, NDA approvals (if any), and product development activities comprising the technology, Crohn&rsquo;s Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Crohn&#8217;s Disease Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Crohn&rsquo;s disease is a chronic inflammatory disease of the gastrointestinal tract, where inflammation extends all the way through the intestinal wall from mucosa to serosa. It is a relapsing and remitting disease. Initially only a small segment of the gastrointestinal tract may be involved, but Crohn&rsquo;s disease has the potential to progress extensively.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Find out more about Crohn&#8217;s Disease Therapeutics Assessment @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/crohns-disease-cd-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Crohn&#8217;s Disease Preclinical and Discovery Stage Products<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Crohn&#8217;s Disease Emerging Drugs Profile<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Guselkumab: Janssen<\/li>\n<li>RHB-104: RedHill Biopharma<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Crohn&rsquo;s Disease Pipeline Therapeutics Assessment<\/strong><\/p>\n<p style=\"text-align: justify;\">There are approx. 90+ key companies which are developing the Crohn&rsquo;s Disease therapies. The Crohn&rsquo;s Disease companies which have their Crohn&rsquo;s Disease drug candidates in the most advanced stage, i.e. Phase III include, Janseen.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&rsquo;s Crohn&#8217;s Disease pipeline report covers around 4+ products under different phases of clinical development like<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Late stage products (Phase III)<\/li>\n<li>Mid-stage products (Phase II)<\/li>\n<li>Early-stage product (Phase I) along with the details of<\/li>\n<li>Pre-clinical and Discovery stage candidates<\/li>\n<li>Discontinued &amp; Inactive candidates<\/li>\n<li>Route of Administration<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Crohn&rsquo;s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Oral<\/li>\n<li>Intravenous<\/li>\n<li>Subcutaneous<\/li>\n<li>Intramuscular<\/li>\n<li>Topical.<\/li>\n<li>Molecule Type<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Crohn&#8217;s Disease Pipeline Products have been categorized under various Molecule types such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Monoclonal Antibody<\/li>\n<li>Peptides<\/li>\n<li>Polymer<\/li>\n<li>Small molecule<\/li>\n<li>Gene therapy<\/li>\n<li>Product Type<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Learn more about the emerging Crohn&#8217;s Disease Pipeline Therapies @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/crohns-disease-cd-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Crohn&#8217;s Disease Clinical Trials Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Crohn&#8217;s Disease Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage- Global<\/li>\n<li>Crohn&#8217;s Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono\/Combination<\/li>\n<li>Crohn&#8217;s Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III<\/li>\n<li>Crohn&#8217;s Disease Companies- Janssen, RedHill Biopharma, Amgen, Pfizer, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Abbvie, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, Priothera, and others.<\/li>\n<li>Crohn&rsquo;s Disease Pipeline Therapies- Etrasimod, Infliximab, MEDI2070, Filgotinib, Risankizumab 600 mg IV, CT-P13, and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Dive deep into rich insights for new drugs for Crohn&#8217;s Disease Treatment, Visit @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/crohns-disease-cd-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Crohn&#8217;s Disease Market Drivers and Barriers, and Future Perspective<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<ol style=\"text-align: justify;\" start=\"1\">\n<li>Introduction<\/li>\n<li>Executive Summary<\/li>\n<li>Crohn&rsquo;s Disease: Overview<\/li>\n<li>Pipeline Therapeutics<\/li>\n<li>Therapeutic Assessment<\/li>\n<li>Crohn&rsquo;s Disease &ndash; DelveInsight&rsquo;s Analytical Perspective<\/li>\n<li>In-depth Commercial Assessment<\/li>\n<li>Crohn&rsquo;s Disease Collaboration Deals<\/li>\n<li>Late Stage Products (Registered)<\/li>\n<li>Infliximab biosimilar: Amgen<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Late Stage Products (Phase III)<\/li>\n<li>Guselkumab: Janssen<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Mid Stage Products (Phase II\/III)<\/li>\n<li>ABX464: Pfizer<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Mid Stage Products (Phase II)<\/li>\n<li>Mocravimod: Priothera<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Early Stage Products (Phase I)<\/li>\n<li>IMU-856: Immunic<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Preclinical Stage Products<\/li>\n<li>INV-88: Innovimmune Biotherapeutics<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Discovery Stage Products<\/li>\n<li>DNL975: Denali Therapeutics<\/li>\n<li>Inactive Products<\/li>\n<li>Crohn&rsquo;s Disease Key Companies<\/li>\n<li>Crohn&rsquo;s Disease Key Products<\/li>\n<li>Crohn&rsquo;s Disease- Unmet Needs<\/li>\n<li>Crohn&rsquo;s Disease- Market Drivers and Barriers<\/li>\n<li>Crohn&rsquo;s Disease- Future Perspectives and Conclusion<\/li>\n<li>Crohn&rsquo;s Disease Analyst Views<\/li>\n<li>Crohn&rsquo;s Disease Key Companies<\/li>\n<li>Appendix<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>For further information on the Crohn&#8217;s Disease Pipeline therapeutics, reach out to&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/crohns-disease-cd-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Crohn&#8217;s Disease Unmet Needs and Analyst Views<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56402.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=crohns-disease-pipeline-emerging-drugs-clinical-trials-fda-approvals-2024-updated\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=crohns-disease-pipeline-emerging-drugs-clinical-trials-fda-approvals-2024-updated\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight&rsquo;s, &ldquo;Crohn&rsquo;s Disease Pipeline Insight 2024&rdquo; report provides comprehensive insights about 90+ companies and 90+ pipeline drugs in Crohn&rsquo;s Disease pipeline landscape. It covers the Crohn&#8217;s Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/crohns-disease-pipeline-emerging-drugs-clinical-trials-fda-approvals-2024-updated_685803.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,413],"tags":[],"class_list":["post-685803","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/685803","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=685803"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/685803\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=685803"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=685803"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=685803"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}